SCHEMBL25822660

SCHEMBL25822660

O=C(ON1CCN(c2ccc(-c3ccc(OCc4ccccc4)nc3OCc3ccccc3)cc2F)CC1)c1ccccc1

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GRM5 P41594 3/20 0.42
FFAR4 Q5NUL3 3/20 0.40
KMT2A Q03164 2/20 0.37
MAPT P10636 4/20 0.36
ALDH1A1 P00352 3/20 0.36
LMNA P02545 2/20 0.36
TSHR P16473 2/20 0.36
NPC1 O15118 1/20 0.36
HPGD P15428 1/20 0.36
ALOX15 P16050 1/20 0.36
MAPK1 P28482 1/20 0.36
NPSR1 Q6W5P4 1/20 0.36
HSD17B10 Q99714 1/20 0.36
POLB P06746 1/20 0.36
SMN1; SMN2 Q16637 1/20 0.36
NPY2R P49146 2/20 0.36
NOX1 Q9Y5S8 1/20 0.36
MEN1 O00255 1/20 0.36
FEN1 P39748 1/20 0.35
SLC6A9 P48067 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29013165 0.87 GRM5 (0.48) GRM5FFAR4KMT2AMAPTALDH1A1
SCHEMBL25822642 0.84 MAPT (0.46) GRM5FFAR4KMT2AMAPTALDH1A1
SCHEMBL29013177 0.83 FFAR4 (0.47) GRM5FFAR4KMT2AALDH1A1NPC1
SCHEMBL27452094 0.83 GRM5 (0.41) GRM5FFAR4KMT2AALDH1A1
SCHEMBL30796430 0.83 GRM5 (0.41) GRM5FFAR4KMT2AALDH1A1
SCHEMBL26642195 0.82 TLR9 (0.46) GRM5MAPTALDH1A1LMNATSHR
SCHEMBL25822405 0.82 FFAR4 (0.60) FFAR4
SCHEMBL25938824 0.82 GRM5 (0.40) GRM5FFAR4KMT2AMAPTALDH1A1
SCHEMBL24753633 0.82 HTR1A (0.46) FFAR4
SCHEMBL35212210 0.81 HRH4 (0.42) GRM5FFAR4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11912710-B2 Substituted pyrimido[4,5-b][1,4]diazepines as PLK1 degradation inducers UPPTHERA, INC. (KR) 2024-02-27 US disclosed
US-20230219966-A1 NOVEL PLK1 DEGRADATION INDUCING COMPOUND UPPTHERA, INC. (KR) 2023-07-13 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230219966-A1 NOVEL PLK1 DEGRADATION INDUCING COMPOUND PLK1, BUB1B, BUB1 GRM5 3397/4885FFAR4 4754/4885KMT2A 1840/4885
US-11912710-B2 Substituted pyrimido[4,5-b][1,4]diazepines as PLK1 degradation inducers PLK1, BUB1B, BUB1 GRM5 1390/4885FFAR4 4733/4885KMT2A 1115/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.